The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
And this to me is the interesting question, right? which is when you look at some of the Alzheimer's biomarkers um which are improving improving significantly um it begs the question should this be part of the playbook for an individual who's at high risk especially given that we now I think really understand how to make sure people don't lose weight and don't lose lean mass and therefore I suspect don't lose bone density and all these other things that matter
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
there's obviously positive effects you see like reduced Alzheimer's disease incidence with people taking these GLP1 receptor agonist
The preponderance of evidence suggests that patients who take these have an improvement in brain uh connectivity and cognitive performance especially in memory tests and this is the important part Nick these are improvements that are better than the uh effects that we see in patients who lose a similar amount of weight and achieve a similar amount of uh uh glycemic control.